Lhermitte-Duclos disease (LDD) is a rare cerebellar tumor associated with Cowden disease (CD) and germline mutations in the PTEN gene. To further define these relationships, we reviewed clinical and pathologic findings in 31 LDD cases and analyzed the status of the PTEN pathway in 11 of them. We hypothesized that the granule cell hypertrophy in LDD is secondary to activation of mammalian target of rapamycin (mTOR), a downstream effector in the PTEN/AKT pathway and a major regulator of cell growth. Histopathologically, in addition to the classical findings of LDD, we observed prominent vascular proliferation and vacuolization of the white matter in many of the lesions. Four patients met diagnostic criteria for CD, and many of the remaining patients had some clinical features of CD. Immunohistochemical analysis showed high levels of phospho-AKT and phospho-S6 in the large ganglionic cells forming the lesions, indicating activation of the PTEN/AKT/mTOR pathway and suggesting a central role for mTOR in the pathogenesis of LDD. These data support recommendations for genetic testing and screening for CD in patients with LDD and suggest a novel therapy for LDD through pharmacologic inhibition of mTOR.
INTRODUCTION
Lhermitte-Duclos disease (LDD), also known as dysplastic cerebellar gangliocytoma, is a rare cerebellar lesion characterized by cellular enlargement mostly restricted to the internal granule cell layer (1, 2) . The pathologic basis of LDD has been long debated, as is has features of both a neoplasm and a hamartoma (3) . Although the lesion is histopathologically benign, recurrences following surgical resection are not uncommon, raising the question of the mechanism underlying these recurrences. LDD is associated with the familial hamartoma-neoplasia syndrome Cowden disease (CD), and both conditions are linked to germline mutations in the phosphatase and tensin homologue (PTEN) gene on chromosome 10 (4-7). Although these associations are well documented, the precise relationships among LDD, CD, and germline PTEN mutations are less clear, as not all patients with LDD develop the clinical manifestations of CD, and some patients with LDD lack germline mutations in PTEN (6). Furthermore, not all patients with germline PTEN mutations manifest CD (8) . A more precise understanding of the molecular defects underlying these conditions will be required for targeted pharmacotherapies to be of use in LDD and CD patients. Our improved understanding of the PTEN signaling cascade, as well as the development of new murine LDD models, allows these issues to be addressed.
The product of the PTEN gene is a dual specificity phosphatase that negatively regulates signal transduction in the phosphatidylinositol 3-kinase (PI3K)/PTEN/AKT pathway (9) . This pathway, perhaps better characterized as a group of interconnected pathways, regulates such fundamental cellular processes as apoptosis, growth, migration, and differentiation (9) (10) (11) . Inactivation of PTEN results in increased levels of phosphorylated AKT (p-AKT), promoting cell growth, proliferation, and survival through multiple downstream effectors (Fig. 1) . One of these pathways, which includes mammalian target of rapamycin (mTOR), is an important regulator of protein synthesis and cell growth (12) . mTOR phosphorylates S6K which, in turn, leads to increased levels of phospho-S6 (p-S6). Antibodies specific for the phosphorylated, activated forms of AKT and S6 have been developed and allow pathway status to be analyzed in formalin-fixed tissues (13) .
Recently created, conditional Pten knockout mice also facilitate the analysis of human LDD by suggesting possible mechanisms through which the lesions arise. Selective inactivation of Pten in neurons is sufficient to impair migration of granule cell precursors and disrupt regulation of cell size in a cell-autonomous fashion, producing a phenotype with striking similarities to human LDD (14) (15) (16) . Examination of these mice at various time points during development reveals that some granule cells fail to migrate inward from the external granule cell layer and remain on the surface of the brain or in the molecular layer where they are transformed over time into ganglion cells (14, 15) . High levels of p-Akt are observed in these cells, consistent with the loss of Pten inhibition (14) . In addition, increased levels of p-S6 are observed in the abnormally enlarged neurons, indicating activation of mTOR (17) . The effect of Pten loss on cell size requires mTOR, as treatment with CCI-779, a specific inhibitor of mTOR, decreases the levels of phospho-S6 and reverses the cellular hypertrophy (17) .
In order to further define the histopathologic and molecular characteristics of LDD, we reviewed 31 cases. We assessed the role of the PI3K pathway in human LDD and the potential for pharmacologic therapy using mTOR inhibitors, by analyzing key members of the pathway using immunohistochemistry. Our data demonstrate activation of the mTOR pathway in human LDD and suggest that mTOR inhibitors may be an effective alternative or adjunct to surgical intervention.
MATERIALS AND METHODS
Thirty-one cases of LDD were collected from the surgical pathology and autopsy files of the Johns Hopkins Hospital, Baltimore, MD; the Armed Forces Institute of Pathology, Washington, DC; and the University of Florida, Gainesville, FL. Detailed clinical information and/or autopsy findings were available in 16 cases. These data were reviewed for features associated with CD, and the diagnosis of CD was based on established criteria (18) . LDD is a major criterion for the clinical diagnosis of CD. Other major criteria include breast cancer, megalencephaly (. 97 th percentile), thyroid cancer (follicular and papillary), and endometrial carcinoma. Minor criteria include benign thyroid lesions such as goiter, mental retardation, hamartomatous intestinal polyps, fibrocystic change of the breast, lipomas, fibromas, and genitourinary tumors or malformations. Approximately 15 of the cases were previously reported in abstract form (19) .
Formalin-fixed, paraffin-embedded tissue was stained with hematoxylin and eosin. In 11 of the 31 cases, tissue blocks or unstained slides were available for immunohistochemistry. Immunohistochemistry was performed for PTEN (1:50, Neomarkers, Fremont CA), phospho-AKT and phospho-S6 (1:50 and 1:300, respectively, Cell Signaling, Charlottesville, VA), MIB-1 (1:1000, DakoCytomation, Carpinteria, CA), and glial fibrillary acidic protein (GFAP, 1:6000, DakoCytomation). For PTEN, endothelial cells served as an internal positive control. Cerebellum from a conditional Pten knockout mouse also served as negative and positive controls for PTEN and p-AKT, respectively (14) . Finally, subependymal giant cell astrocytomas from tuberous sclerosis patients, in which p-S6 is present due to mutation in TSC1/TSC2, were used as positive controls for p-S6. PTEN, p-AKT, and p-S6 immunoreactivity was considered positive if greater than 25% of the lesional ganglion cells were reactive. The intensity of immunoreactivity for PTEN was graded as greater than endothelial cells (++), equal to endothelial cells (+), or negative (2). p-AKT and p-S6 immunoreactivity was graded as strongly positive (++), weakly positive (+), or negative (2).
RESULTS

LDD Commonly Coexists with CD and Thyroid Disease
The clinical features are summarized in Table 1 . Demographic information was unavailable in 2 cases; of the remaining patients, 15 were female and 14 were male. The age at presentation varied from 13 to 63 years, with a mean of 34.8 years. Headache, nausea/vomiting, and vertigo were the most common presenting symptoms. Additional signs and symptoms attributable to increased intracranial pressure were also seen. In 2 patients (cases 23 and 24), death occurred due to obstructive hydrocephalus with subsequent herniation. Radiologically, evidence of mass effect and hydrocephalus was common, with compression of the fourth ventricle, and tonsillar herniation in several cases. The average size of the tumor was 4.5 cm in greatest dimension (n = 8). Of the 21 cases for which laterality information was available, 13 were in the right cerebellum and 8 were in the left cerebellum. Calcification was seen by CT scan in 1 patient. The lesion typically showed diminished signal on T1-weighted MR images, and slight contrast enhancement was seen in a minority of cases. A characteristic finding on T2-weighted images was the striped or laminated appearance of the lesion, with multiple, narrow, high signal bands alternating with isointense strips (Fig. 2) . Clinical information on extra-central nervous system (CNS) disease was available for approximately one half of the patients and suggests that LDD commonly coexists with other abnormalities, including those that define CD (Table 1 ). In our series, 4 patients (cases 1, 19, 24, and 25) met criteria for the diagnosis of CD. Thyroid disease was present in 9 patients (cases 1, 5, 8, 10, 17, 20, 24, 25, and 26) and included hyperthyroidism, hypothyroidism, goiter, and adenoma. Thyroidectomy had been performed in 2 patients for unknown reasons. Incidental meningiomas were identified in 2 patients (cases 3 and 20) . Clinical follow-up information or autopsy results were available in 13 patients. Follow-up interval ranged from 5 months to 24 years. Four patients (cases 13, 18, 25 and 27) underwent at least 1 resection for recurrent tumor. The initial resection was subtotal in 2 of these cases; the extent of resection in the other 2 cases is unknown. Time from initial surgery to recurrence ranged from 4 to 11 years. Two recurrences followed initial diagnosis in the youngest patient in the series (case 18), 7 and 11 years after the initial resection.
Aberrant Granule Cell Migration and Hypertrophy, but Not Proliferation, Characterize LDD
The characteristic histopathologic findings of LDD, replacement of the internal granule layer (IGL) by hypertrophic ganglion cells, abnormal molecular layer myelination, and an attenuated or absent Purkinje cell layer (Fig. 3A, B, D) , were present in all cases. However, the severity of this phenotype varied between patients and within individual lesions. In some regions, only the most superficial IGL cells were increased in size (Fig. 3A) , while in others, most (Fig.  3B) or all of the IGL was replaced by abnormal ganglion cells. GFAP immunostains were largely negative in regions with only superficial IGL involvement, indicating this was not merely Bergmann gliosis. In the most severely affected regions, the molecular layer (ML) showed increased cellularity as well. In some cases, the increased cellularity in the ML was composed of granule neurons. In others, the cells in the hypercellular ML appeared similar to the atypical cells in the IGL. The presence of both ectopic granule neurons and dysplastic ganglion cells in the ML and under the pia (Fig. 3C) suggests that, as in Pten-deficient mice, aberrant migration is followed by hypertrophy.
Additional microscopic changes included bizarre, hyperchromatic cells in some lesions (Fig. 3D ) and microscopic calcification in most cases (Fig. 3E) . Many of the lesions were highly vascular, with dense capillary networks and/or ectatic, thin-walled blood vessels (Fig. 3F) . One final common feature was extensive vacuolization of the cerebellar white matter (Fig. 4A) . Similar but less extensive vacuoles were present in the molecular layer of many cases (Fig. 4B) . Although the contents of the vacuoles were not apparent in most cases, in one they appeared to contain proteinaceous fluid. Vacuolization of the white matter and molecular layer could contribute to the characteristic striped pattern of the lesion on MRI. With regard to the proliferation potential of LDD, the Ki67 index was either low (1%-2%) or zero. Moreover, most of the cells with nuclear immunoreactivity for Ki67 were perivascular and morphologically consistent with inflammatory cells. No cells with obvious ganglion cell morphology were immunoreactive for Ki67.
PTEN/AKT/S6 Signaling Is Active in Ganglionic LDD Cells
Paraffin-embedded tissue blocks or unstained slides were available in 11 cases. The results of the immunohistochemical analysis of PTEN, p-AKT, and p-S6 are shown in Table 2 . Immunohistochemistry for PTEN varied considerably among the cases. In the majority (6 of 9, [67%]), immunoreactivity for PTEN in lesional cells was focal and/or weak, while robust signal was seen in endothelium (Fig. 5A) . Greater than 25% of tumor cells were positive, however, in 3 specimens (cases 16, 18, and 22) . In 1 of these cases (case 18), PTEN signal exceeded that in adjacent blood vessels (Fig. 5B) . In positive cases, PTEN immunoreactivity was seen predominantly in the cytoplasm of ganglion cells. Nuclear staining was present, however, in occasional cells of uncertain origin with small round nuclei and scant cytoplasm.
Immunoreactivity for p-AKT was more uniform with 9 of 10 (90%) cases showing at least weak signal in greater than 25% of lesional cells (Fig. 5C ). The lesion with absent p-AKT staining (Fig. 5D ) was the tumor with the greatest PTEN immunoreactivity (Fig. 5B) . Staining for p-AKT was mostly cytoplasmic in the abnormal ganglion cells, although nucleolar immunoreactivity was seen in 2 cases. Of the 3 pathway members analyzed, results with antibody to p-S6 were the most robust. All 11 cases in which p-S6 immunohistochemistry was performed were scored as positive, with the majority of these (9 of 11 [82%]) showing strong cytoplasmic signal in the majority of enlarged ''ganglionic'' cells (Fig. 5E, F) .
DISCUSSION
The 31 cases of LDD we report all demonstrated the classical hallmarks of LDD, including replacement of the granule cell layer by larger cells with a neuronal phenotype, loss of Purkinje cells, and expansion and hypermyelination of the molecular layer. The findings in murine LDD models are similar to those we observe in human specimens, including ectopic granule cells and ganglion cells in the molecular layer (ML) and beneath the pia (Fig. 3C) . We believe the extra granule and ganglion cells subjacent to the pia and in the molecular layer in human cases arise through defects in migration and maturation similar to those seen in mice. Partially affected regions, with increased cell size seen only in the superficial internal granule cell layer (IGL, Fig. 3A) , are also present in both humans and mice. These data suggest that human LDD represents a defect in the regulation of cell size superimposed upon aberrant migration of granule cell precursors. The spatial heterogeneity of the lesion, including the presence of partially affected regions, may account for tumor ''recurrences.'' Regrowth of LDD lesions following initial surgical resection is not uncommon (20) (21) (22) and has been cited as evidence of a neoplastic rather than hamartomatous/developmental etiology in LDD. Four of 13 (31%) patients with longterm follow-up in the present series underwent at least 1 resection for recurrent tumor. The finding of minimal or incipient lesions coexisting with more advanced changes in our series and in previous reports on large resection or autopsy specimens (1, 23) suggests that partial resection may account for many such recurrences. Furthermore, LDD can be a multifocal process, as minimal changes have been reported in the cerebellar hemisphere contralateral to the mass lesion (23) . These subtle hypertrophic changes, observed at the histopathologic level, either at the edges of resected lesions or at distant sites, would presumably not be apparent grossly or on MRI. Cells in such genetically affected but grossly normal tissue, left behind in initial operations, could continue to hypertrophy, resulting in tumor ''recurrence.''
Whether from the original tumor bed or a separate focus, growth of tumor in LDD appears to result from increasing size of individual neurons rather than neuronal proliferation. Although mitotic figures have been reported in LDD (1, 23), we did not appreciate them in any of the cases in this series, including the recurrent lesions. The majority of studies, including ours, have failed to identify significant proliferative activity using immunohistochemical markers (2, 21, 24, 25) . Furthermore, the Pten conditional knockout mouse model, in which neuronal size can be measured at different time points in the lifespan of the animal, supports the concept that growth of tumor in LDD arises from hypertrophy of individual cells rather than hyperplasia (14) . In addition to dysregulation of cell size, PTEN deficiency could account for the prominent vascular changes in LDD (Fig. 3F) , as evidence suggests that the PI3K/AKT pathway promotes angiogenesis via upregulation of vascular endothelial growth factor (VEGF), an effect that may be mediated by hypoxia-inducible factor-1 (26) .
Our immunohistochemical results implicate the PTEN/AKT/mTOR pathway in the pathogenesis of the majority of LDD cases. Most of the lesions were negative for PTEN, suggesting loss of the inhibitory influence of this protein on the pathway. Consistent with this interpretation, nearly all of the tumors showed immunoreactivity for p-AKT in the abnormal ganglion cells. Similar data on PTEN expression and p-AKT levels in LDD have been presented recently by Zhou et al (6) . We extend these findings using immunohistochemistry for p-S6, which is downstream of mTOR. Robust activation of S6 was present in all of the cases examined, making it the most commonly detected molecular alteration in LDD lesions. These data strongly suggest that activation of mTOR is central to the pathogenesis of LDD and raise the possibility of a novel pharmacotherapy for LDD using inhibitors of mTOR, such as CCI-779.
Cases of LDD in very young patients may provide insight into the relationships among LDD, CD, and PTEN gene mutation. Although early and late LDD lesions appear histopathologically identical, a recent genetic analysis suggests that childhood-onset LDD may be distinguished from adult-onset LDD by the lack of germline PTEN mutations and absence of the CD phenotype (6). Our findings support this hypothesis. The youngest patient at the time of LDD diagnosis in the present series (case 18) was 13 years old. Immunohistochemistry showed high levels of PTEN and low levels of p-AKT in this specimen, the only lesion in this series to show this pattern (Fig. 5B, D) . These findings are consistent with a lack of PTEN mutation and intact PTEN inhibition of the pathway. Although this patient underwent surgery twice for recurrent tumor, follow-up over 13 years revealed no evidence of CD. These findings suggest a pathogenesis for childhoodonset LDD that does not involve PTEN and does not affect tissues outside the CNS. Despite apparent intact function of PTEN in the case of childhood-onset LDD, the lesion showed high levels of activated S6 (Fig. 5F, inset) , suggesting activation of mTOR downstream of AKT.
Disrupted signaling in the PI3K pathway downstream of AKT has been linked to other developmental/hamartomatous CNS lesions. Patients with tuberous sclerosis complex (TSC) develop cortical tubers, regions of disorganized neural tissue featuring prominent, large, bizarre cells with both neuronal and glial differentiation. Subependymal giant cell astrocytoma (SEGA), a low-grade neoplasm characterized by large cells with glioneuronal differentiation and increased cytoplasmic volume, also occurs almost exclusively in TSC. TSC is caused by mutations in the TSC1 or TSC2 genes (27, 28) . Genetic studies in Drosophila indicate that the homologous gene products in this highly conserved pathway are regulatory proteins positioned at intermediate levels in the PI3K signaling cascade, downstream of AKT and upstream of TOR (29, 30) . Mutation results in loss of inhibition of TOR and ultimately increased levels of p-S6. Recent reports indicate that cells in both cortical tubers and SEGA express high levels of p-S6 (31, 32) .
In summary, we report a large series of LDD cases and find a strong association between LDD and CD. This supports current recommendations for genetic testing and close scrutiny for signs of CD in patients diagnosed with LDD (18) . Our data suggest that the pathogenesis of LDD, in most cases, is related to loss of the inhibitory influence of PTEN on the PI3K pathway, resulting in deleterious effects on neuronal migration and regulation of cell size. Thus, LDD is perhaps best considered a hypertrophic phenomenon superimposed upon a developmental malformation. Finally, our findings strongly support the concept that activation of the AKT/mTOR signaling pathway plays a major role in this hypertrophy, suggesting that mTOR inhibitors are a potential treatment for LDD.
